Shauna Whisenton

COVID-19 Health Alert for Patients and Caregivers

With COVID-19 at the forefront of nearly everyone’s minds, the Medical and Research Advisory Committee (MARAC) at SCDAA wants to provide information to our sickle cell community. Educating yourself about the coronavirus reduces anxiety and empowers you to protect yourself – and your family – from getting sick. The potential health risk posed by COVID-19 …

COVID-19 Health Alert for Patients and Caregivers Read More »

ASH COVID-19 Resources for Hematologists

The United States and countries around the world face a major public health concern with the current outbreak of the novel (new) coronavirus (COVID-19). This webpage is intended to help healthcare providers stay abreast of the best and latest resources for hematologists affected by COVID-19. Read more about ASH’s COVID-19 resources here. ASH President’s Message: …

ASH COVID-19 Resources for Hematologists Read More »

ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies

Sickle cell disease is the most common inherited red blood cell disorder in the United States, and it affects millions of people worldwide. In people living with SCD, the red blood cells, which are normally round, become crescent or sickle-shaped which contributes to the vaso-occlusive crises these patients experience. People with SCD suffer from an …

ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies Read More »

How a Clinical Trial Participant Became an Advocate for the Sickle Cell Community

Shauna Whisenton was once an individual living with sickle cell disease (SCD). Now she’s an advocate for better therapies, a cure, and a better understanding of SCD. Whisenton’s journey was tough. She was hospitalized, received anti-rejection medications, and had to undergo chemotherapy. She persevered with support from family and her medical team. For Whisenton, treatment …

How a Clinical Trial Participant Became an Advocate for the Sickle Cell Community Read More »

FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell Disease

On November 15, 2019, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older. “Hope has never …

FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell Disease Read More »

NIH/Gates Foundation Collaboration to Develop Accessible, Gene-Based Cures for Sickle Cell Disease and HIV

Initial investment aims to advance accessible and scalable candidate interventions into clinical trials within 10 years. The collaboration will align aggressive, high-reward research efforts to accelerate progress on shared gene-based strategies (depicted in green) to cure sickle cell disease and HIV that are available globally including in low-resource settings, while continuing to invest in other …

NIH/Gates Foundation Collaboration to Develop Accessible, Gene-Based Cures for Sickle Cell Disease and HIV Read More »

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top